2016 American Transplant Congress
The Effect of Tocilizmab Treatment (TCZ-Rx) on IgG Subclasses in HLA-sensitized (HS) Kidney Transplant Patients Treated with TCZ.
Background: Antibody-mediated rejection (ABMR) is a major obstacle for successful transplant in HS patients. TCZ has anti-B cell and anti-inflammatory properties. We have reported its…2016 American Transplant Congress
Kidney Graft Homing of De Novo Donor Specific HLA Antibodies Is an Early Step within the Antibody-Mediated Graft Damage Process.
In this study, by a parallel analysis on sera and graft biopsies we have analyzed, in a pediatric cohort of unsensitized recipients of a first…2016 American Transplant Congress
Risk of Acute Rejection Among ABO Incompatible Living Donor Kidney Recipients.
School of Medicine, University of Alabama at Birmingham, Birmingham, AL.
Background: ABO incompatible (ABOi) live donor kidney transplantation (LDKT) holds the potential for increased access to transplantation for ESRD patients. Concerns remain related to the…2016 American Transplant Congress
Tacrolimus as a Tool for Intracellular Assessment of von Willebrand Factor Production by Activated Human Glomerular Endothelial Cells.
Renal Division, University Health Center (CHU) of Quebec, Laval University, Quebec, QC, Canada.
Background: Von Willebrand factor (vWF) is a prothrombotic mediator stored in intracytoplasmic granules within endothelial cells and is released by endothelial exocytosis, leading to microangiopathic…2016 American Transplant Congress
Inflammation Amplifier, a Chemokine Inducer in Non-Immune Cells in Kidney Transplantation Graft.
Introduction: Inflammation amplifier (IA), a local chemokine inducer in non-immune cells is induced by the simultaneous activation of NFκB and STATs (IL-17, TNFα, and IL-6)…2016 American Transplant Congress
Prognosis Value of the Presence and Persistence of C1q Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation.
Purpose : Longitudinal study of C1q complement fraction binding capacity of donor specific anti-HLA antibodies (DSAs) as a pronostic marker in acute antibody-mediated rejection.Methods :…2016 American Transplant Congress
Anti-HLA Antibodies in Allogeneic and Autologous Hematopoietic Stem Cell Transplantation.
Introduction: Anti-HLA antibodies have been associated with graft rejection in solid organ and hematopoietic stem cell transplantation (HSCT). The aim of this study was describe…2016 American Transplant Congress
A Novel Study to Determine the Association of Pre-Transplant Donor Specific Antibody and AT1R Antibody with Kidney Transplant Outcomes Prior to Adoption of Solid Phase Antibody Assays.
University of Wisconsin, Madison.
Background: Studies assessing the risk of pre-transplant antibodies are generally restricted to low levels of donor specific antibody (DSA). Here we analyze pre-transplant HLA DSA,…2016 American Transplant Congress
Tocilizumab as Treatment for Persistent Chronic Active Antibody Mediated Rejection.
Columbia University Medical Center, NYC.
Intro: CAAMR is an increasingly recognized cause of renal allograft failure with limited treatment options. Many patients with CAAMR have engagement of both T and…2016 American Transplant Congress
Comparison of EDTA, DTT and Dilutions to Abrogate the Prozone Effect in Luminex-Based HLA Antibody Assays.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ.
Mean fluorescence intensity (MFI) values obtained from Luminex-based single antigen bead (SAB) assays is a semi-quantitative result used to determine the relative strength of HLA…
American Transplant Congress abstracts